Larimar shareholders approve increase in authorized shares to 215M; reelect three directors

Larimar Therapeutics, Inc.

Shareholders approved amendment increasing authorized common shares from 115M to 215M (89.7M for, 1.05M against).
Three Class III directors (Frank Thomas, Carole Ben-Maimon, Joseph Truitt) reelected with >66M votes each.
Advisory vote on executive compensation passed (73.8M for, 1.5M against); one-year frequency selected.
Ratification of PricewaterhouseCoopers as independent auditor for FY 2026 (90.8M for).

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.